NASDAQ:RXST RxSight (RXST) Stock Price, News & Analysis $25.22 -0.85 (-3.26%) Closing price 04:00 PM EasternExtended Trading$25.22 0.00 (0.00%) As of 04:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About RxSight Stock (NASDAQ:RXST) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get RxSight alerts:Sign Up Key Stats Today's Range$25.11▼$26.2050-Day Range$24.76▼$35.8452-Week Range$24.64▼$66.54Volume291,254 shsAverage Volume528,134 shsMarket Capitalization$1.02 billionP/E RatioN/ADividend YieldN/APrice Target$51.63Consensus RatingModerate Buy Company OverviewRxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.Read More… Remove Ads RxSight Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreRXST MarketRank™: RxSight scored higher than 58% of companies evaluated by MarketBeat, and ranked 460th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingRxSight has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageRxSight has only been the subject of 4 research reports in the past 90 days.Read more about RxSight's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for RxSight are expected to grow in the coming year, from ($0.70) to ($0.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of RxSight is -30.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of RxSight is -30.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRxSight has a P/B Ratio of 5.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about RxSight's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.81% of the float of RxSight has been sold short.Short Interest Ratio / Days to CoverRxSight has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in RxSight has recently increased by 8.30%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRxSight does not currently pay a dividend.Dividend GrowthRxSight does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.81% of the float of RxSight has been sold short.Short Interest Ratio / Days to CoverRxSight has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in RxSight has recently increased by 8.30%, indicating that investor sentiment is decreasing significantly. News and Social Media3.3 / 5News Sentiment0.85 News SentimentRxSight has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for RxSight this week, compared to 5 articles on an average week.MarketBeat Follows2 people have added RxSight to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, RxSight insiders have sold 141.44% more of their company's stock than they have bought. Specifically, they have bought $44,993.00 in company stock and sold $108,632.00 in company stock.Percentage Held by InsidersOnly 9.36% of the stock of RxSight is held by insiders.Percentage Held by Institutions78.78% of the stock of RxSight is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about RxSight's insider trading history. Receive RXST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RxSight and its competitors with MarketBeat's FREE daily newsletter. Email Address RXST Stock News HeadlinesRxSight, Inc. (NASDAQ:RXST) Receives $51.63 Average Price Target from AnalystsMarch 10 at 1:37 AM | americanbankingnews.comRxSight, Inc. (NASDAQ:RXST) Just Reported, And Analysts Assigned A US$44.80 Price TargetFebruary 28, 2025 | finance.yahoo.comPlease don’t die on me"Please don’t die on me," the nurse begged as Porter Stansberry lay in a hospital bed, his heart stopped from years of pushing himself too hard. At his lowest point, he realized that everything had gone wrong, and he was forced to rebuild—not just his health, but his entire life and fortune. After clawing his way out of that abyss, Porter discovered a life-changing investment strategy, one that allowed him to rebuild his wealth far faster and with less risk than he ever imagined. This approach helped him earn enormous returns outside of the volatile stock market, and now he’s sharing it with you. While most won’t believe it’s possible, Porter is asking you to open your mind and consider a new way of investing—one that could transform your financial future, just as it did for him.March 13, 2025 | Porter & Company (Ad)Morgan Stanley Sticks to Their Buy Rating for RxSight (RXST)February 28, 2025 | markets.businessinsider.comRxSight price target lowered to $44 from $58 at BTIGFebruary 26, 2025 | markets.businessinsider.comRxSight stock jumps as Q4 earnings beat expectations, guidance strongFebruary 26, 2025 | investing.comWells Fargo Reaffirms Their Hold Rating on RxSight (RXST)February 26, 2025 | markets.businessinsider.comStifel Nicolaus Sticks to Their Hold Rating for RxSight (RXST)February 26, 2025 | markets.businessinsider.comSee More Headlines RXST Stock Analysis - Frequently Asked Questions How have RXST shares performed this year? RxSight's stock was trading at $34.38 at the start of the year. Since then, RXST shares have decreased by 26.8% and is now trading at $25.1540. View the best growth stocks for 2025 here. How were RxSight's earnings last quarter? RxSight, Inc. (NASDAQ:RXST) posted its earnings results on Tuesday, February, 25th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by $0.25. The company had revenue of $40.21 million for the quarter, compared to analyst estimates of $40.23 million. RxSight had a negative net margin of 23.92% and a negative trailing twelve-month return on equity of 14.00%. When did RxSight IPO? RxSight (RXST) raised $125 million in an initial public offering on Friday, July 30th 2021. The company issued 7,350,000 shares at a price of $16.00-$18.00 per share. Who are RxSight's major shareholders? RxSight's top institutional shareholders include RA Capital Management L.P. (9.29%), Vanguard Group Inc. (5.91%), Bank of America Corp DE (5.36%) and Artisan Partners Limited Partnership (3.85%). Insiders that own company stock include Ronald M Md Kurtz, Eric Weinberg, Ilya Goldshleger, Julie Andrews, Robert Keith Warner, William J Phd Link, Shelley B Thunen, Shweta Maniar and Jesse Anderson Corley. View institutional ownership trends. How do I buy shares of RxSight? Shares of RXST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of RxSight own? Based on aggregate information from My MarketBeat watchlists, some other companies that RxSight investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), e.l.f. Beauty (ELF), ServiceNow (NOW), Arista Networks (ANET) and Disc Medicine (IRON). Company Calendar Last Earnings2/25/2025Today3/13/2025Next Earnings (Estimated)5/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Ophthalmic goods Sub-IndustryMedical Equipment Current SymbolNASDAQ:RXST CIK1111485 Webwww.rxsight.com Phone949-521-7830FaxN/AEmployees220Year FoundedN/APrice Target and Rating Average Stock Price Target$51.63 High Stock Price Target$73.00 Low Stock Price Target$33.00 Potential Upside/Downside+104.3%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($0.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-48,610,000.00 Net Margins-23.92% Pretax Margin-23.91% Return on Equity-14.00% Return on Assets-12.51% Debt Debt-to-Equity RatioN/A Current Ratio12.67 Quick Ratio11.71 Sales & Book Value Annual Sales$139.93 million Price / Sales7.31 Cash FlowN/A Price / Cash FlowN/A Book Value$4.47 per share Price / Book5.65Miscellaneous Outstanding Shares40,491,000Free Float36,532,000Market Cap$1.02 billion OptionableOptionable Beta1.22 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:RXST) was last updated on 3/13/2025 by MarketBeat.com Staff From Our PartnersElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredYour Wealth is Under AttackHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RxSight, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RxSight With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.